SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Beyond Meat, Inc. engages in the provision of plant-based meats. Its products include ready-to-cook meat under The Beyond Burger and Beyond Sausage brands, and frozen meat, namely, Beyond Chicken Strips and Beyond Beef Crumbles. The company was founded by Ethan Walden Brown and Brent Taylor in 2009 and is headquartered in El Segundo, CA.

Beyond Meat Inc

Beyond Meat is trending due to a potential short squeeze, fueled by high short interest and significant retail buying. The community is laser-focused on breaking key resistance levels and pushing the stock higher, with some drawing comparisons to the GME and AMC rallies of 2021. Record-breaking trading volume is adding to the frenzy as investors look to capitalize on the stock's upward momentum.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards following earnings, with community chatter focusing on a miss attributed to a Brazilian tax dispute, although some suspect subscriber losses are the real issue. While some see a buying opportunity and potential for a quick rebound, others anticipate further declines, citing rich valuation, competition, and concerns over content quality. The discussion also includes potential support levels and price targets.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending downwards, sparking heavy debate among investors about potential bottom levels and the sustainability of its valuation despite a major Microsoft deal and upcoming earnings; community sentiment is mixed, with some calling for aggressive dip buying while others express concern over the stock's persistent decline amid broader market strength. Discussions also involve the potential impact of AI spending trends and the company's diverse business segments beyond data centers.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid discussions about a potential correction and volatility in the quantum computing sector, with debates on the company's valuation and future prospects; some traders are betting against the stock while others are holding or buying, citing long-term potential and upcoming catalysts. Community members are actively discussing technical analysis, potential price targets, and the impact of warrant redemptions and broader market conditions on QBTS.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as investors digest recent Q3 earnings, which beat estimates and raised forward guidance, though the stock experienced a sharp reversal following the ER call. Community discussions revolve around speculation of a potential rug pull and market manipulation by shorts, while others see it as a buying opportunity. VRT's connection to the AI data center infrastructure boom and partnerships with companies like NVIDIA continue to be a key talking point.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is trending following news of a $5 million production order for its 800G optical engines, a significant increase from previous orders. The community is speculating about the customer behind this order, with some suggesting a connection to META through Luxshare. Discussions also revolve around the company's potential to disrupt the AI interconnectivity landscape.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending due to a significant stock plunge following mixed interim results from its ARCT-032 cystic fibrosis trial, specifically showing limited lung function improvement. Despite the drop, some investors believe the stock is oversold, citing the company's broader drug pipeline and positive aspects of the trial data, such as mucus reduction. The community is actively discussing the potential for a bounce, strategic entry points, and the long-term value of the company's mRNA technology.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the stock experiences significant volatility, leading to a mix of bullish and bearish sentiment within the trading community. Discussions revolve around the recent price drop, potential support levels, and comparisons to other quantum computing stocks, with some traders viewing it as a buying opportunity while others express concerns about the SPAC structure and sector-wide pressures. Despite the turbulence, the upcoming NVIDIA GTC event and Infleqtion's involvement are focal points for potential catalysts.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

SLDP is trending due to growing optimism around solid-state battery technology and its potential to revolutionize the EV industry. Community members are discussing partnerships with major players like BMW and SK On, highlighting recent milestones in pilot plant completion and electrolyte production. The stock is also gaining traction as a 100% USA-based company amid discussions of rare earth mineral dependencies.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending amidst discussions of potential market manipulation following its earnings report, with community members expressing frustration over the stock's price action despite strong results. Some investors believe large entities are strategically driving the price down to profit from put options, while others remain optimistic about the company's long-term potential within the crypto and AI sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revelation Biosciences, Inc. (REVB) on Tuesday announced positive safety and activity data from an early-stage trial of its investigational drug Gemini in stage 3 and 4 chronic kidney disease patients.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">trial </a>enrolled 40 patients aged 32 to 78 years. Different patients were treated at four different doses to evaluate the safety of Gemini, Revelation’s formulation of phosphorylated hexaacyl disaccharide, which aims to trigger the innate immune system to release pro-inflammatory cytokines and stimulate immune cell responses. Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli, the company said.However, shares of the company tumbled 17% at the time of writing, after the company reported that three severe adverse events were identified at the highest dose of Gemini in the study, including chills, nausea, and vomiting. However, this was all resolved in three hours or less, the company noted, while adding that other reported adverse events were either mild or moderate.On Stocktwits, retail sentiment around <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">REVB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_24_31_PM_png_d57363a4a3.webp" alt="REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user termed the news as “clear bullish” and opined that the stock could explode at any moment.<stembedurl>https://stocktwits.com/hassan101/message/627968361</stembedurl>Another user expressed surprise at the stock drop.<stembedurl>https://stocktwits.com/Chickendinner1/message/627961173</stembedurl>Revelation CEO James Rolke said that the results of the study demonstrate the potential of Gemini to be a “game-changer” in the treatment of acute and chronic inflammation. The company is now looking forward to a meeting with the FDA later this year to discuss the program's advancement, he added.Chronic kidney disease is caused by chronic inflammation. Progression of chronic kidney damage often leads to end-stage renal disease with the need for dialysis or transplantation, the company noted.REVB stock is down by about 89% this year and by about 94% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.

Equity

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.


Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split.&nbsp;The split is expected to be effective before the market opens on July 7.&nbsp;Revelation plans to conduct the reverse split to meet Nasdaq's minimum bid requirement.The reverse split, approved at a special shareholder meeting held on June 23, will affect all outstanding shares and adjust related equity instruments, including options, warrants, and restricted stock units (RSUs).&nbsp;Revelation will retain its current ticker symbol “REVB.”Separately, Revelation stated that enrollment is expected to conclude this month in its Phase 1b trial evaluating Gemini in patients with chronic kidney disease.&nbsp;Topline results are expected soon after.Earlier this year, the company said that Gemini reduced inflammation in lab tests involving human immune cells.&nbsp;Cells primed with Gemini showed lower levels of proinflammatory cytokines and higher levels of protective anti-inflammatory markers when exposed to known inflammation triggers, including HMGB-1 and bacterial LPS.&nbsp;The company said that similar effects could be observed in patients, supporting Gemini’s potential in treating inflammation-driven conditions.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.One user described the 1-for-3 reverse split as “small” and suggested that good news could follow shortly.&nbsp;<stembedurl>https://stocktwits.com/SkyLonger/message/619658091</stembedurl>Another user acknowledged the initial panic-driven selloff but argued the situation was different from typical reverse split moves, adding that “bigger news” may be on the way.<stembedurl>https://stocktwits.com/lookgoodplaygood22/message/619658026</stembedurl>Revelation’s stock has declined 92.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split. 

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly. 

FTSE 100 today: BoE rate decision looms; Vodafone names CFO; Whitbread reports

Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.

Frasers Group decides not to make offer for Revolution Beauty

Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer   Revolution Beauty Group   PLC (LON:REVB).

Frasers explores potential bid for Revolution Beauty, company confirms

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the...

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the...

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following...

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of...

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Revelation Biosciences Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

REVB
Revelation Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REVB News

REVBRevelation Biosciences Inc